Spray-dried co-amorphous Tadalafil ternary mixtures
a promising platform towards the enhancement of solubility and bioavailability
DOI:
https://doi.org/10.1590/s2175-97902022e20622Keywords:
Tadalafil, Spray drying, Co-amorphous, Solubility, BioavailabilityAbstract
Tadalafil (Tad) is a poorly water-soluble drug (BCS class II) that is used for the treatment of erectile dysfunction. An enhancement of aqueous solubility is vital to accelerate its onset of action and subsequently enhance its therapeutic effect. Binary and ternary mixtures of Tad with different amino acids (histidine, valine, alanine or arginine) and other excipients (mannitol and SLS) were prepared and then spray dried. The solubilizing efficiency and physicochemical characterization of all spray dried mixtures of Tad were studied. The optimum formulation was investigated in male rats to determine the onset of erection and the pharmacokinetic parameters of Tad. In general terms, the drug solubility of spray-dried formulae was enhanced compared to the crystalline form of the drug as a result of the formation of co-amorphous structures. The final result revealed that the Tad/alanine/mannitol spray-dried mixture (F10) showed the highest solubility and an improvement in its physicochemical characteristics. Moreover, F10 showed a significantly faster erection in rats with an improvement in Tad pharmacokinetic parameters when compared to the crystalline drug. Thus, F10 is selected as a promising formulation that successfully enhanced the bioavailability and the therapeutic efficacy of Tad.
Downloads
References
Aboul-Enein HY, Ali I. Determination of tadalafil in pharmaceutical preparation by HPLC using monolithic silica column. Talanta. 2005;65(1):276-280.
Babu NJ, Nangia A. Solubility advantage of amorphous drugs and pharmaceutical cocrystals. Cryst Growth Des. 2011;11(7):2662-2679.
Baek JS, Pham CV, Myung CS, Cho CW. Tadalafil-loaded nanostructured lipid carriers using permeation enhancers. Int J Pharm. 2015;495(2):701-709.
Craye G, Löbmann K, Grohganz, H, Rades T, Laitinen R. Characterization of amorphous and co-amorphous simvastatin formulations prepared by spray drying. Molecules. 2015;20(12):21532-21548.
Démuth B, Nagy ZK, Balogh A, Vigh T, Marosi G, Verreck G, et al. Downstream processing of polymer-based amorphous solid dispersions to generate tablet formulations. Int J Pharm . 2015;486(1-2):268-286.
França MT, Marcos TM, Pereira RN, Stulzer HK. Could the small molecules such as amino acids improve aqueous solubility and stabilize amorphous systems containing Griseofulvin? Eur J Pharm Sci. 2020;143:e105178.
Hancock BC, Zografi G. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci. 1997;86(1):1-12.
Hauss DJ. Oral lipid-based formulations. Adv Drug Deliv Rev. 2007;59(7):667-676.
Hussar DA. New drugs of 2002. J Am Pharm Assoc. 2003;43(2):207-248.
Janssens S, Van den Mooter G. Review: physical chemistry of solid dispersions. J Pharm Pharmacol. 2009;61(12):1571-1586.
Jensen KT, Blaabjerg LI, Lenz E, Bohr A, Grohganz H, Kleinebudde P, et al. Preparation and characterization of spray-dried co-amorphous drug-amino acid salts. J Pharm Pharmacol . 2016;68(5):615-624.
Jensen KT, Löbmann K, Rades T, Grohganz H. Improving co-amorphous drug formulations by the addition of the highly water soluble amino acid, Proline. Pharmaceutics. 2014;6(3):416-435.
Jermain SV, Brough C, Williams RO 3rd. Amorphous solid dispersions and nanocrystal technologies for poorly water- soluble drug delivery - An update. Int J Pharm . 2018;535(1-2):379-392.
Kasten G, Löbmann K, Grohganz H, Rades T. Co-former selection for co-amorphous drug-amino acid formulations. Int J Pharm . 2019;557:366-373.
Löbmann K, Grohganz H, Laitinen R, Strachan C, Rades T. Amino acids as co-amorphous stabilizers for poorly water soluble drugs - Part 1: Preparation, stability and dissolution enhancement. Eur J Pharm Biopharm. 2013;85(3 Pt B):873-881.
Mande P, Bachhav S, Devarajan P. Bioenhanced advanced third generation solid dispersion of tadalafil: repurposing with improved therapy in pyelonephritis. Asian J Pharm Sci . 2017;12(6):569-579.
Nair A, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016;7(2):27-31.
Nanjwade BK, Derkar GK, Bechra HM, Nanjwade VK, Manvi FV. Design and characterization of nanocrystals of lovastatin for solubility and dissolution enhancement. J Nanomed Nanotechnol. 2011;2(2):1-7.
Rao Q, Qiu Z, Huang D, Lu T, Zhang ZJ, Luo D, et al. Enhancement of the apparent solubility and bioavailability of Tadalafil nanoparticles via antisolvent precipitation. Eur J Pharm Sci. 2019;128:222-231.
Reddy BPK, Reddy YR. Validation and stability indicating RP-HPLC method for the determination of sildenafil citrate in pharmaceutical formulations and human plasma. E-J Chem. 2008;5(S2):1117-1122.
Soni TG, Desai JU, Nagda CD, Gandhi TR, Chotai NP. Mathematical evaluation of similarity factor using various weighing approaches on aceclofenac marketed formulations by model-independent method. Pharmazie. 2008;63(1):31-34.
Srinarong P, De Waard H, Frijlink HW, Hinrichs WLJ. Improved dissolution behavior of lipophilic drugs by solid dispersions: The production process as starting point for formulation considerations. Expert Opin Drug Deliv. 2011;8(9):1121-1140.
Sun DD, Lee PI. Evolution of supersaturation of amorphous pharmaceuticals : Nonlinear rate of supersaturation generation regulated by matrix diffusion. Mol Pharm. 2015;12(4):1203-1215.
Vo CLN, Park C, Lee BJ. Current trends and future perspectives of solid dispersions containing poorly water- soluble drugs. Eur J Pharm Biopharm . 2013;85(3 Pt B):799-813.
Williams HD, Trevaskis NL, Charman SA, Shanker RM, Charman WN, Pouton CW, et al. Strategies to address low drug solubility in discovery and development. Pharmacol Rev. 2013;65(1):315-499.
Wlodarski K, Sawicki W, Haber K, Knapik J, Wojnarowska Z, Paluch M, et al. Physicochemical properties of tadalafil solid dispersions - Impact of polymer on the apparent solubility and dissolution rate of tadalafil. Eur J Pharm Biopharm . 2015;94:106-115.
Wlodarski K, Sawicki W, Paluch KJ, Tajber L, Grembecka M, Hawelek L, et al. The influence of amorphization methods on the apparent solubility and dissolution rate of tadalafil. Eur J Pharm Sci. 2014;62:132-140.
Wlodarski K, Tajber L, Sawicki W. Physicochemical properties of direct compression tablets with spray dried and ball milled solid dispersions of tadalafil in PVP-VA. Eur J Pharm Biopharm . 2016;109:14-23.
Wu W, Löbmann K, Rades T, Grohganz H. On the role of salt formation and structural similarity of co-formers in co- amorphous drug delivery systems. Int J Pharm . 2018;535(1-2):86-94.
Yadav PS, Kumar V, Singh UP, Bhat HR, Mazumder B. Physicochemical characterization and in vitro dissolution studies of solid dispersions of ketoprofen with PVP K30 and d-mannitol. Saudi Pharm J. 2013;21(1):77-84.
Zheng W, Jain A, Papoutsakis D, Dannenfelser RM, Panicucci R, Garad S. Selection of oral bioavailability enhancing formulations during drug discovery. Drug Dev Ind Pharm. 2012;38(2):235-247.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.
